Unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T-cell malignancies

被引：0

作者：

Jinqi Huang

Stepanov Alexey

Jian Li

Terri Jones

Geramie Grande

Lacey Douthit

Jun Xie

Danna Chen

Xiaolei Wu

Maschan Michael

Changchun Xiao

Jiangning Zhao

Xuehua Xie

Jia Xie

Xiao Lei Chen

Guo Fu

Gabibov Alexander

Chi-Meng Tzeng

机构：

[1] Xiamen University,Translational Medicine Research Center (TMRC), School of Pharmaceutical Sciences

[2] The Scripps Research Institute,Department of Chemistry

[3] Russian Academy of Sciences,M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry

[4] Xiamen University,State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences

[5] The Affiliated Hospital of Putian University,Department of Immunology and Microbiology

[6] ProteinT Biotechnology Ltd. Co. Tianjin Airport Free Trade Zone,Department of Hematology

[7] Dmitrii Rogachev Federal Research Center for Pediatric Hematology,Department of Oncology

[8] Oncology and Immunology,School of Pharmacology

[9] The Scripps Research Institute,undefined

[10] zhongshan Hospital of Xiamen University,undefined

[11] The first hospital of Putian City,undefined

[12] Nanjing Tech University,undefined

来源：

Leukemia | 2019年 / 33卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2315 / 2319

页数：4

共 50 条

[21] Detection of clonal evolution in a case of T-cell lymphoma by T-cell receptor Vβ CDR3 "spectratype"
Bonfigli, S
Pistidda, P
Guiso, L
Dore, F
Longinotti, M
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 294 - 294
[22] T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
Tang, Lu
Zhang, Yinqiang
Hu, Yu
Mei, Heng
BIOMED RESEARCH INTERNATIONAL, 2021, 2021
[23] T cell senescence and CAR-T cell exhaustion in hematological malignancies
Kasakovski, Dimitri
Xu, Ling
Li, Yangqiu
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[24] T cell senescence and CAR-T cell exhaustion in hematological malignancies
Dimitri Kasakovski
Ling Xu
Yangqiu Li
Journal of Hematology & Oncology, 11
[25] T-cell neoplasias and secondary malignancies after CAR-T cell therapy: current knowledge, risk factors, and implications from CAR-T engineering strategies
Maurer, Katie
Jacobson, Caron A.
LEUKEMIA & LYMPHOMA, 2025,
[26] CARγδ-T cell for solid tumor immunotherapy based on tumor specific CDR3δ
Teng, D.
Chen, H.
Zhang, J.
He, W.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 150 - 150
[27] T-cell lymphoma: the CAR-T revolution is coming
Grover, Natalie S.
Beaven, Anne W.
BLOOD, 2024, 143 (13) : 1201 - 1202
[28] Emergence of Malignant T-Cell Intraclonal CDR3 Variants in Mycosis Fungoides
Gleason, Laura
Cohen, Alexa
South, Andrew P.
Porcu, Pierluigi
Nikbakht, Neda
JAMA DERMATOLOGY, 2023, 159 (08) : 888 - 890
[29] Standardized analysis for the quantification of Vβ CDR3 T-cell receptor diversity
Long, S. Alice
Khalili, Jahan
Ashe, Jimiane
Berenson, Ron
Ferrand, Christophe
Bonyhadi, Mark
JOURNAL OF IMMUNOLOGICAL METHODS, 2006, 317 (1-2) : 100 - 113
[30] T-CELL RECEPTORS EXPRESSED BY T-CELLS PROLIFERATING TO THE GOODPASTURE ANTIGEN SHARE COMMON CDR3 SEQUENCES
FISHER, M
PUSEY, CD
REES, AK
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1995, 6 (03): : 828 - 828

← 1 2 3 4 5 →